JP2012506898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506898A5 JP2012506898A5 JP2011533721A JP2011533721A JP2012506898A5 JP 2012506898 A5 JP2012506898 A5 JP 2012506898A5 JP 2011533721 A JP2011533721 A JP 2011533721A JP 2011533721 A JP2011533721 A JP 2011533721A JP 2012506898 A5 JP2012506898 A5 JP 2012506898A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- ylamine
- tautomer
- stereoisomer
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 SAR543 Chemical compound 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 5
- 229960005167 everolimus Drugs 0.000 claims 5
- 229940124302 mTOR inhibitor Drugs 0.000 claims 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 5
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 claims 4
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 4
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 claims 4
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 4
- 229950009216 sapanisertib Drugs 0.000 claims 4
- 229960002930 sirolimus Drugs 0.000 claims 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 4
- 229960000235 temsirolimus Drugs 0.000 claims 4
- 229950009819 zotarolimus Drugs 0.000 claims 4
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- ICSNLGPSRYBMBD-UHFFFAOYSA-N alpha-aminopyridine Natural products NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000012609 Cowden disease Diseases 0.000 claims 2
- 201000002847 Cowden syndrome Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 208000008069 Geographic Atrophy Diseases 0.000 claims 2
- 208000031309 Hypertrophic Familial Cardiomyopathy Diseases 0.000 claims 2
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000033793 Neuroendocrine tumor of stomach Diseases 0.000 claims 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- JROFGZPOBKIAEW-UHFFFAOYSA-N chembl2132692 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1C1CCC(C(O)=O)CC1 JROFGZPOBKIAEW-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000006692 familial hypertrophic cardiomyopathy Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 201000011587 gastric lymphoma Diseases 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 201000008632 juvenile polyposis syndrome Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 201000004931 neurofibromatosis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000015768 polyposis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 2
- 208000036506 well differentiated low or intermediate grade gastric neuroendocrine tumor Diseases 0.000 claims 2
- 238000006029 Jeger synthesis reaction Methods 0.000 claims 1
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168044.9 | 2008-10-31 | ||
| EP08168044 | 2008-10-31 | ||
| PCT/EP2009/064274 WO2010049481A1 (en) | 2008-10-31 | 2009-10-29 | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014181069A Division JP2015013883A (ja) | 2008-10-31 | 2014-09-05 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012506898A JP2012506898A (ja) | 2012-03-22 |
| JP2012506898A5 true JP2012506898A5 (enExample) | 2012-12-06 |
Family
ID=40332588
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533721A Withdrawn JP2012506898A (ja) | 2008-10-31 | 2009-10-29 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 |
| JP2014181069A Withdrawn JP2015013883A (ja) | 2008-10-31 | 2014-09-05 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 |
| JP2016134514A Ceased JP2017002058A (ja) | 2008-10-31 | 2016-07-06 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 |
| JP2018136756A Pending JP2018197243A (ja) | 2008-10-31 | 2018-07-20 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014181069A Withdrawn JP2015013883A (ja) | 2008-10-31 | 2014-09-05 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 |
| JP2016134514A Ceased JP2017002058A (ja) | 2008-10-31 | 2016-07-06 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 |
| JP2018136756A Pending JP2018197243A (ja) | 2008-10-31 | 2018-07-20 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20110195966A1 (enExample) |
| EP (1) | EP2349275B1 (enExample) |
| JP (4) | JP2012506898A (enExample) |
| KR (1) | KR20110090911A (enExample) |
| CN (2) | CN105030784A (enExample) |
| AU (1) | AU2009309616B2 (enExample) |
| BR (1) | BRPI0921802A8 (enExample) |
| CA (1) | CA2736361C (enExample) |
| ES (1) | ES2627677T3 (enExample) |
| MX (1) | MX2011004585A (enExample) |
| RU (2) | RU2538683C2 (enExample) |
| WO (1) | WO2010049481A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| US8476431B2 (en) * | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| CA2937492C (en) | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
| EP2393827B1 (en) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
| GB2478556A (en) * | 2010-03-09 | 2011-09-14 | Myrovlytis Technology Ventures Ltd | A composition for use in the treatment of Birt-Hogg-Dubô sydrome |
| CN103391780B (zh) * | 2011-02-16 | 2015-08-19 | 诺瓦提斯公司 | 用于治疗神经变性疾病的治疗剂的组合物 |
| TWI592411B (zh) * | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
| KR20130131461A (ko) * | 2011-03-07 | 2013-12-03 | 폰다지오네 텔레톤 | Tfeb 변종 및 그의 용도 |
| WO2012148846A1 (en) * | 2011-04-25 | 2012-11-01 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
| JP6047149B2 (ja) * | 2011-05-04 | 2016-12-21 | インテリカイン， エルエルシー | 併用の医薬組成物およびその使用 |
| MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| CN104080786A (zh) * | 2011-11-08 | 2014-10-01 | 因特利凯有限责任公司 | 使用多种药剂的治疗方案 |
| US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
| UY34632A (es) * | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| RU2012112128A (ru) * | 2012-03-29 | 2013-10-10 | Холин Максим Николаевич | ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
| CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
| CA2903979A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| HK1214533A1 (zh) | 2013-03-15 | 2016-07-29 | 基因泰克公司 | 治疗癌症和预防癌症耐药性的方法 |
| TWI710558B (zh) * | 2013-05-01 | 2020-11-21 | 瑞士商赫孚孟拉羅股份公司 | 二雜芳基化合物及其用途 |
| KR20160058774A (ko) | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
| CN103483345B (zh) * | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| EP3283127B1 (en) * | 2015-04-15 | 2020-02-26 | University of Massachusetts | Compositions and methods for xi chromosome reactivation |
| US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| JP2020500930A (ja) | 2016-11-23 | 2020-01-16 | ノバルティス アーゲー | エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法 |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| KR20210158019A (ko) | 2020-06-23 | 2021-12-30 | 주식회사 온코빅스 | 포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| CN112294967A (zh) * | 2020-09-30 | 2021-02-02 | 四川大学 | 一种mTOR抑制剂与抗癌药物的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100919266B1 (ko) * | 2000-06-26 | 2009-09-30 | 엔벤타 바이오파마슈티컬스 코포레이션 | 인간 파필로마 바이러스 치료법 |
| TW200626610A (en) * | 2004-10-13 | 2006-08-01 | Wyeth Corp | Analogs of 17-hydroxywortmannin as PI3K inhibitors |
| CN101222925A (zh) * | 2005-07-20 | 2008-07-16 | 诺瓦提斯公司 | 嘧啶基氨基苯甲酰胺和mTOR激酶抑制剂的组合产品 |
| KR101464384B1 (ko) * | 2005-11-22 | 2014-11-21 | 쿠도스 파마슈티칼스 리미티드 | ｍＴＯＲ 억제제로서 피리도피리미딘, 피라조피리미딘 및피리미도피리미딘 유도체 |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| EP1981890A2 (en) * | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
| WO2007120897A2 (en) * | 2006-04-13 | 2007-10-25 | The Trustees Of Columbia University In The City Of New York | Compositions and intraluminal devices for inhibiting vascular stenosis |
| CA2675558A1 (en) * | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| RU2478387C2 (ru) * | 2007-02-20 | 2013-04-10 | Новартис Аг | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR |
| AU2008335469A1 (en) * | 2007-12-13 | 2009-06-18 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
-
2009
- 2009-10-29 CA CA2736361A patent/CA2736361C/en not_active Expired - Fee Related
- 2009-10-29 WO PCT/EP2009/064274 patent/WO2010049481A1/en not_active Ceased
- 2009-10-29 EP EP09744391.5A patent/EP2349275B1/en not_active Not-in-force
- 2009-10-29 RU RU2011121508/15A patent/RU2538683C2/ru not_active IP Right Cessation
- 2009-10-29 MX MX2011004585A patent/MX2011004585A/es active IP Right Grant
- 2009-10-29 BR BRPI0921802A patent/BRPI0921802A8/pt not_active IP Right Cessation
- 2009-10-29 CN CN201510402018.9A patent/CN105030784A/zh active Pending
- 2009-10-29 JP JP2011533721A patent/JP2012506898A/ja not_active Withdrawn
- 2009-10-29 CN CN2009801431736A patent/CN102202668A/zh active Pending
- 2009-10-29 KR KR1020117009771A patent/KR20110090911A/ko not_active Ceased
- 2009-10-29 AU AU2009309616A patent/AU2009309616B2/en not_active Ceased
- 2009-10-29 ES ES09744391.5T patent/ES2627677T3/es active Active
- 2009-10-29 US US13/123,956 patent/US20110195966A1/en not_active Abandoned
-
2014
- 2014-04-15 RU RU2014115188/15A patent/RU2014115188A/ru not_active Application Discontinuation
- 2014-09-05 JP JP2014181069A patent/JP2015013883A/ja not_active Withdrawn
-
2015
- 2015-11-24 US US14/950,869 patent/US20160136175A1/en not_active Abandoned
-
2016
- 2016-07-06 JP JP2016134514A patent/JP2017002058A/ja not_active Ceased
-
2018
- 2018-01-16 US US15/872,043 patent/US20180133226A1/en not_active Abandoned
- 2018-07-20 JP JP2018136756A patent/JP2018197243A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011121508A (ru) | Комбинация ингибитора фосфатидилинозитол-3-киназы (р13к) и ингибитора mtor | |
| Finn | Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition | |
| Moreira-Pais et al. | Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention | |
| JP2014513097A5 (enExample) | ||
| JP2014502957A5 (enExample) | ||
| JP6086902B2 (ja) | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤およびｍＴＯＲ阻害剤の組み合わせ | |
| EP1986632A1 (en) | Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic | |
| JP2010532364A (ja) | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 | |
| JP2017507151A5 (enExample) | ||
| CN102834094B (zh) | 有机化合物的组合产品及其制药用途 | |
| RU2016135413A (ru) | Фармацевтические комбинации, включающие ингибитор pi3k, для лечения рака | |
| Giles et al. | Novel therapies for patients with chronic myeloid leukemia | |
| JP2022500423A5 (enExample) | ||
| Barod et al. | Pathway Paralysis: Identification of Novel Therapeutic Targets for Renal Carcinoma. | |
| Cordiner et al. | Metastatic Renal Cell Carcinoma: A Review of Systemic Treatment Options in 2011 | |
| Samaras et al. | Protein kinase inhibitors in the treatment of malignant liver and kidney tumors |